News

Home > News > SJTU Research Group Makes a Major Breakthrough in the New Target of Cancer Treatment

SJTU Research Group Makes a Major Breakthrough in the New Target of Cancer Treatment

June 13, 2017      Author: Guo Hao

Recently, Professor Li Dawei, from SJTU School of Pharmacy, has made great breakthroughs in research on new targets for tumor therapy. Research revealed the new role of high expression of Anterior Gradient Protein 2 (AGR2) in the development of breast cancer mechanism. At the same time, the humanized antibody, Agtuzumab (18A4Hu), which was developed according to the relevant mechanism, also showed excellent therapeutic effect in anti-tumor and drug combination. A series of related studies were published in the Oncogene on May 8 this year, and the Biochemical and Biophysical Research Communications on May 2016.

 

Li Dawei believes that it is significant for the active exploration and development of new tumor treatment, and immunotherapy development based on AGR2 needs to be carried out in depth. He hopes that relevant researches will benefit clinical patients through follow-up researches and extensive social cooperation.

 


 

Translated by Wang Ying   Reviewed by Wang Bingyu